The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Dupixent is a prescription medication used to treat various conditions, including allergic rhinitis, asthma, and atopic ...

A new study published in the Journal of the European Academy of Dermatology and Venerology found dupilumab to have a ...

Brimonidine, latanoprost, tralokinumab, dupilumab, and allopurinol may increase the risk of conjunctivitis, research suggests.

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

The chronic pruritus market is expected to grow across the 7MM, driven by the introduction of innovative therapies like ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.